Indivior Share Discussion Threads

[steeplejack] 24/9/2020 08:49

Indivior notes that business performance during the third quarter of 2020 has been in-line with the FY 2020 Planning Assumptions it outlined on July 30th as part of its H1 2020 results announcement, with the exception that SUBOXONE® Film share has continued to perform ahead of historical industry analogues (1) and Group expectations.

[maywillow] 21/9/2020 19:41

NOW THATS A REAL JUMP BUT WHY


INDIVIOR PLC (INVVY)

Delayed Quote. Delayed OTC Bulletin Board - Other OTC - 09/21 07:26:46 pm

10.88 USD +37.20%

[waldron] 21/9/2020 09:21

Upcoming events on INDIVIOR

October/29/2020 Q3 2020 Earnings Release

[grupo] 21/9/2020 08:50

Price (GBX)
115.90 -4.69% (-5.70)

Open / Last close
122.70 / 121.60

High / Low
124.60 / 115.80

Bid / Offer
115.90 / 116.30

Special Condition: -
Trading Status: Regular Trading
FTSE All-Share
As at 21.09.20 08:33:05 - All data delayed at least 15 minutes

[jgrabar] 09/9/2020 12:37

Longer term INDV holders can make demands for governance reforms and seek restitution on behalf of the company, for the failures in corporate governance the lead to the guilty pleas and $600 million fines. Cash incentives are typically awarded to the demanding shareholder(s) as well. Another side of investing when these situations arise. Feel free to message me here to learn more.

[meijiman] 09/9/2020 12:31

It's the electric chair for him then.......

[grupo] 05/9/2020 18:15

RNS Number : 1399Y

Indivior PLC

04 September 2020

September 4, 2020

Indivior PLC - Board Announcement

Indivior PLC announces that the Chair of the Board, Howard Pien, who has been on a medical leave since June 15, 2020, has notified the Board of his resignation with immediate effect.

Daniel Tassé, who was appointed as Interim Chair in Mr Pien's absence, will continue to act as Interim Chair until the Board appoints Mr Pien's successor. The Board will commence a process to identify a successor.

Mr Tasse joined the Board in 2014 and was appointed Senior Independent Director in 2016 ( bio ). He is a member of the Audit and Remuneration Committees.

[ariane] 04/9/2020 18:37

Fri, 4th Sep 2020 17:31
RNS Number : 1399Y
Indivior PLC
04 September 2020


September 4, 2020



Indivior PLC - Board Announcement



Indivior PLC announces that the Chair of the Board, Howard Pien, who has been on a medical leave since June 15, 2020, has notified the Board of his resignation with immediate effect.



Daniel Tassé, who was appointed as Interim Chair in Mr Pien's absence, will continue to act as Interim Chair until the Board appoints Mr Pien's successor. The Board will commence a process to identify a successor.



Mr Tasse joined the Board in 2014 and was appointed Senior Independent Director in 2016 (bio). He is a member of the Audit and Remuneration Committees.



Investor Contact:

Jason Thompson, IndiviorVice President, Investor Relations+1 [e-mail]

[adrian j boris] 02/9/2020 20:38

FTSE 250 Adds:



Indivior

[sarkasm] 01/9/2020 10:21

Newtyn Management, LLC




New York, United States

Just bought near 4pc

[waldron] 31/8/2020 08:38

THE WISH LIST GIVING BOXES,Supports and Resistences to determine channels and trends together with broker targets which might of course make you smile or and smirk


90 to 100p
110 to 120p$$$$$$$$$$$$$ WE ARE HERE $$$$$$$$$$$$$$$
120 to 130p
130 to 140p
140 to 150p
150 to 160p
160 to 170pCiti target 165p
170 to 180p
180 to 190p
190 to 200p Jefferies target 200p





DECEMBER END 2019 GIVES 39p which puts us into the 30 to 40p BOX again


June ends in the 80 to 90p BOX at 83p

July ends at 137.60p

August ends at 118.70p


current strong support seems to be 111p

current strong resistence seems to be 142.40p

[waldron] 28/8/2020 07:48

It seems theres possible strong support at 111p

[jgrabar] 26/8/2020 17:54

The Department of Justice’s (“DOJ”) $600 million civil and criminal settlement against Indivior related to marketing the opioid-addiction-treatment drug Suboxone, combined with the prior, larger, $1.4 billion settlement with Reckitt Benckiser Group PLC, Indivior’s former parent company, inked in 2019 yield longer term shareholder standing in potential derivative matters.

These matters seek to enhance corporate governance and go after D&O policies to get funds paid in fines back into corporate coffers. Can also allow for incentive awards to shareholders.

Best,

Josh
[e-mail]

[sarkasm] 26/8/2020 08:04

August 25, 2020
DOJ Demonstrates Continued Focus on Opioid Crisis with $600 Million Criminal and Civil Settlement Against Indivior Solutions, Indivior Inc., and Indivior plc


Dorsey & Whitney LLP

The Department of Justice’s (“DOJ”) most recent settlement with Indivior Solutions, Inc., Indivior Inc., and Indivior plc (together, “Indivior”) demonstrates not only that the DOJ is continuing its pursuit of claims and settlements related to the opioid crisis, but also that the DOJ is searching for creative penalties beyond large monetary payouts.

In a July 24, 2020 press release, the DOJ announced a $600 million civil and criminal settlement against Indivior related to marketing the opioid-addiction-treatment drug Suboxone. This settlement follows a larger, $1.4 billion settlement with Rickeitt Benckiser Group PLC, Indivior’s former parent company, inked in 2019. The DOJ touts the combined $2 billion value of the 2019 and 2020 settlements as the largest-ever resolution in a case brought by the DOJ involving opioid drugs.

The civil settlement resolves claims from six qui tam lawsuits brought against various combinations of the Indivior entities under the False Claims Act (“FCA”). United States ex rel. Finkelstein v. Reckitt Benckiser Pharms., Inc., No. 14-cv-00059 (W.D. Va.); United States ex rel. Williams v. Reckitt Benckiser, Inc., No. 13-cv-00036 (W.D. Va.); United States ex rel. Lemons v. Reckitt Benckiser Pharms., No. 15-cv-00016 (W.D. Va.); United States ex rel. Kruszewski v. Reckitt Benckiser Pharms., Inc., No. XX-cv-XXXX [UNDER SEAL] (D.N.J.); United States ex rel. Scott v. Reckitt Benckiser Pharms, Inc., No. XX-cv-XXXX [UNDER SEAL] (N.D.J.); United States ex rel. Greene v. Indivior PLC, No. XX-cv-XXXX [UNDER SEAL] (D.N.J.). Under the civil settlement, Indivior Inc. and Indivior plc agreed to pay $300 million, with $209.3 million going to the federal government and $90.7 million going to certain participating states. The amount awarded to the individual whistleblowers has yet to be determined.

While Indivior did not admit fault in its civil settlement, the settlement resolves three main allegations. First, the DOJ alleged Indivior knowingly promoted the sale and use of Suboxone to physicians who were writing prescriptions not for a medically-accepted indication, lacked a legitimate medical purpose, were issued without counseling or psychosocial support, were for unsafe, ineffective, and medically-unnecessary uses, or were often diverted. Second, the DOJ alleged that Indivior knowingly promoted the sale or use of Suboxone Film to physicians and state Medicaid agencies using false and misleading claims that Suboxone Film was less susceptible to accidental pediatric exposure than Suboxone Tablets. And third, the DOJ alleged that Indivior tried to delay the entry of generic competition to control the price of Suboxone—including pricing to federal healthcare programs. Such actions allegedly included the improper submission of a petition to the Food and Drug Administration (“FDA”) claiming that Suboxone Tablet had been discontinued “due to safety concerns” about the tablet formulation of the drug. As part of the criminal resolution, Indivior Solutions pleaded guilty to a one-count felony criminal information charging false statements related to health care matters, in violation of 18 U.S.C. § 1035. See United States v. Indivior Solutions, Inc., 19-cr-00016-JPJ-PMS (W.D. Va.). The plea included an admission that Indivior Solutions made false statements to promote the film version of Suboxone to the Massachusetts Medicaid programs regarding the safety of Suboxone Film around children. The settlement includes a criminal fine, forfeiture, and restitution in the combined amount of $289 million.

The criminal resolution also includes novel, non-monetary components, requiring that Indivior Inc. permanently disband its entire Suboxone sales force and a prohibition from using data obtained from surveys of health care providers for marketing, sales, or proposal purposes. Indivior’s CEO will also be required to annually certify—under penalty of perjury—either that: (1) Indivior was complaint with the Food, Drug, and Cosmetic Act and did not commit health care fraud; or (2) list all of Indivior’s non-compliant activity and the steps taken to remedy it. Finally, Indivior Inc. is also required to remove health care providers from its promotion programs at high risk of inappropriate prescribing. Neither the press release nor settlement materials explain how Indivior is supposed to identify high-risk providers. Failure to meet the above requirements will cause contempt sanctions and a reinstatement of the dismissed charges.

Besides the civil and criminal settlements, Indivior also agreed to a five-year Corporate Integrity Agreement with the Department of Health and Human Services Office of Inspector General, under which Indivior will implement numerous accountability and auditing provisions, including a yearly compliance certification by Indivior executives and Board of Directors, annual risk assessments and other monitoring, and multi-faceted audits conducted by an independent review organization.

These cases serve as a reminder that the DOJ continues to aggressively pursue both civil and criminal claims related to the opioid crisis and provides insight into the non-monetary, compliance-based penalties the DOJ may pursue as part of global civil and criminal resolutions. As the stated by Elton Malone, Assistant Inspector General for Investigations with the Office of Inspector General of the U.S. Department of Health and Human Services, “[t]his resolution, along with our law enforcement partners’ work, should serve as a warning that large companies will face prosecution if they break the law.”

[sarkasm] 26/8/2020 08:03

Judge Allows Additional Antitrust Claims In Indivior Dispute
CPI -
August 25, 2020
law

A district judge has given India-based Dr Reddy’s the greenlight to move forward with its antitrust counterclaims against Indivior.

[the stigologist] 25/8/2020 17:26

Seemed bullish on 'good data' over coming years

[waldron] 25/8/2020 16:44

The company also noted Indivior PLC has started a Phase 1 clinical trial for C4X's novel selective Orexin-1 antagonist, for the treatment of opioid dependence with the first patient now dosed.

The study is expected to complete by year end.

[waldron] 25/8/2020 15:30

C4X Discovery Joins Covid Collaboration With Italian Hospitals

Tue, 25th Aug 2020 12:28

(Alliance News) - Drug discovery firm C4X Discovery Holdings PLC said Tuesday it has entered into a new collaboration with the GEN-COVID consortium, a network of more than 20 hospitals in Italy.

"The collaboration will use the unique mathematical genetic analysis methodology of Taxonomy3 to investigate the role genetics plays in the widely varied disease susceptibility, severity and prognosis observed between individuals with Covid-19," C4X explained.

Taxonomy3 will analyse genetic data from a "significant" number of Covid-19 positive patients collected by the consortium to identify genes associated with severe Covid-19 disease, the drug discovery firm said.

C4X added: "The aim is to identify a unique genetic signature that can successfully predict mild versus severe disease to inform treatment of patients at risk. The analysis may also uncover novel biology driving severity of the disease which may inform potential novel drug targets for treatment."

Chief Executive Clive Dix said: "The disease continues to spread throughout the world and a clear understanding of how it affects people differently remains elusive.

"We believe that genetics may play a role in explaining the differences in an individual's disease susceptibility, severity and prognosis. This is a new area for C4XD and we are excited to be working on such an important project. We remain committed to deliver and drive novel small molecule drugs against challenging targets towards clinical development."

The company also noted Indivior PLC has started a Phase 1 clinical trial for C4X's novel selective Orexin-1 antagonist, for the treatment of opioid dependence with the first patient now dosed.

The study is expected to complete by year end.

Dix continued: "I am delighted to share the progress we have made over recent months across our proprietary portfolio despite the challenges of the Covid-19 pandemic, in particular, the continued headway in our key inflammation programmes.

"Our two most advanced programmes, NRF-2 and IL-17, continue to move forward with one of our lead NRF-2 molecules, C4X_6746, showing significant efficacy in a pre-clinical model of Inflammatory Bowel Disease. This enables expansion of our commercial discussions beyond those partners already engaged in assessing the programme for Pulmonary Arterial Hypertension and Sickle Cell Disease."

Shares in C4X Discovery were down 9.2% in London on Tuesday at 22.25 pence each.

By Paul McGowan; [e-mail]

[waldron] 10/8/2020 10:19

Aggregate of Standard Life Aberdeen plc affiliated investment management entities with delegated voting rights on behalf of multiple managed portfolios

City and country of registered office Edinburgh, Scotland


ONLY A SLIGHT REDUCTION IN HOLDING

[waldron] 08/8/2020 08:47

THE WISH LIST


90 to 100p
110 to 120p$$$$$$$$$$$$$ WE ARE HERE $$$$$$$$$$$$$$$
120 to 130p
130 to 140p
140 to 150p
150 to 160p
160 to 170pCiti target 165p
170 to 180p
180 to 190p
190 to 200p Jefferies target 200p





DECEMBER END 2019 GIVES 39p which puts us into the 30 to 40p BOX again


June ends in the 80 to 90p BOX at 83p

July ends at 137.60p



current strong support seems to be 106p

current strong resistence seems to be 142.40p


The week ends at 119.50p

[sarkasm] 05/8/2020 17:08

Price (GBX)
121.50 -7.74%